Syndecan-1 (CD 138) in Myeloma and Lymphoid Malignancies: A Multifunctional Regulator of Cell Behavior Within the Tumor Microenvironment

References

• Carey D. J. Syndecans: multifunctional cell-surface co-receptors. Biochem. J. 1997; 327: 1–16
   PubMed Web of Science ®Google Scholar
• Bernfield M., Kokenyesi R., Kato M., Hinkes M. T., Spring J., Gallo R. L., Lose E. J. Biology of the syndecans: A family of transmembrane heparan sulfate proteoglycans. Annu. Rev. Cell Biol. 1992; 8: 365–393
   PubMedGoogle Scholar
• Sanderson R. D., Lalor P., Bernfield M. B lymphocytes express and lose syndecan at specific stages of differentiation. Cell Regul. 1989; 1: 27–35
   PubMedGoogle Scholar
• Ridley R. C., Xiao H., Hata H., Woodliff J., Epstein J., Sanderson R. D. Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. Blood 1993; 81: 767–774
   PubMed Web of Science ®Google Scholar
• Gaidano G., Gloghini A., Gattei V., Rossi M. F., Cilia A. M., Godeas C., Degan M., Perin T., Canzonieri V., Aldinucci D., Saglio G., Carbone A., Pinto A. Association of Kaposi's sarcoma-associated herpesvirus-positive primary effusion lymphoma with expression of the CD138/syndecan-1 antigen. Blood 1997; 90: 4894–900
   PubMed Web of Science ®Google Scholar
• Carbone A., Gloghini A., Gattei V., Degan M., Improta S., Aldinucci D., Canzonieri V., Perin T., Volpe R., Gaidano G., Zagonel V., Pinto A. Reed-Sternberg cells of classical Hodgkin's disease react with the plasma cellspecific monoclonal antibody B-B4 and express human syndecan-1. Blood 1997; 89: 3787–3794
   PubMed Web of Science ®Google Scholar
• Carbone A., Gaidano G., Gloghini A., Larocca L. M., Capello D., Canzonieri V., Antinori A., Tirelli U., Falini B., Dalla-Favera R. Differential expression of BCL-6, CD138/syndecan-1, and Epstein-Barr virus-encoded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. Blood 1998; 91: 747–755
   PubMed Web of Science ®Google Scholar
• Wijdenes J., Vooijs W. C., Clement C., Post J., Morard F., Vita N., Laurent P., Sun R. X., Klein B., Dore J. M. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br. J. Haematol. 1996; 94: 318–323
   PubMed Web of Science ®Google Scholar
• Sun R. X., Lu Z. Y., Wijdenes J., Brochier J., Hertog C., Rossi J. F., Klein B. Large scale and clinical grade purification of syndecan-1+ malignant plasma cells. J. Immunol. Methods 1997; 205: 73–79
   PubMed Web of Science ®Google Scholar
• Jourdan M., Ferlin M., Legouffe E., Horvathova M., Liautard J., Rossi J. F., Wijdenes J., Brochier J., Kiein B. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br. J. Haematol. 1998; 100: 637–646
   PubMed Web of Science ®Google Scholar
• Schneider U., Van Lessen A., Huhn D., Serke S. Two subsets of peripheral blood plasma cells defined by differential expression of CD45 antigen. Br. J. Haematol. 1997; 97: 56–64
   PubMed Web of Science ®Google Scholar
• Rawstron A. C., Owen R. G., Davies F. E., Johnson R. J., Jones R. A., Richards S. J., Evans P. A., Child J. A., Smith G. M., Jack A. S., Morgan G. J. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Br. J. Haematol. 1997; 97: 46–55
   PubMed Web of Science ®Google Scholar
• Dhodapkar M. V., Abe E., Theus A., Lacy M., Lang-Ford J. K., Barlogie B., Sanderson R. D. Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation. Blood 1998; 91: 2679–2688
   PubMed Web of Science ®Google Scholar
• Dhodapkar M. V., Kelly T., Theus A., Athota A. B., Barlogie B., Sanderson R. D. Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma. Br. J. Haematol. 1997; 99: 368–371
   PubMed Web of Science ®Google Scholar
• Khoory M. S., Nesheim M. E., Bowie E. J., Mann K. G. Circulating heparan sulfate proteoglycan anticoagulant from a patient with a plasma cell disorder. J. Clin. Invest. 1980; 65: 666–674
   PubMed Web of Science ®Google Scholar
• Palmer R. N., Rick M. E., Rick P. D., Zeller J. A., Gralnick H. R. Circulating heparan sulfate anticoagulant in a patient with a fatal bleeding disorder. N. Engl. J. Med. 1984; 310: 1696–1699
   PubMed Web of Science ®Google Scholar
• Chapman G. S., George C. B., Danley D. L. Heparin-like anticoagulant associated with plasma cell myeloma. Am. J. Clin. Pathol. 1985; 83: 764–766
   PubMed Web of Science ®Google Scholar
• Kaufman P. A., Gockerman J. P., Greenberg C. S. Production of a novel anticoagulant by neoplastic plasma cells: Report of a case and review of the literature. Am. J. Med. 1989; 86: 612–616
   PubMed Web of Science ®Google Scholar
• Subramanian S. V., Fitzgerald M. L., Bernfield M. Regulated shedding of syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation. J. Biol. Chem. 1997; 272: 14713–14720
   PubMed Web of Science ®Google Scholar
• Kainulainen V., Wang H., Schick C., Bernfield M. Syndecans, heparan sulfate proteoglycans, maintain the proteolytic balance of acute wound fluids. J. Biol. Chem. 1998; 273: 11563–11569
   PubMed Web of Science ®Google Scholar
• Fitzgerald M. L., Bernfield M. Shedding of syndecan ectodomains is regulated by multiple pathways and metalloproteinase-dependent. Mol. Biol Cell 1997; 8: 393a
   Google Scholar
• Teoh C., Anderson K. C. Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol. Oncol. Clin. North Am. 1997; 11: 27–42
   PubMed Web of Science ®Google Scholar
• Sanderson R. D., Sneed T. B., Young L. A., Sullivan G. L., Lander A. D. Adhesion of B lymphoid (MPC-11) cells to type I collagen is mediated by integral membrane proteoglycan, syndecan. J. Immunol. 1992; 148: 3902–3911
   PubMed Web of Science ®Google Scholar
• Sanderson R. D., Turnbull J. E., Gallagher J. T., Lander A. D. Fine structure of heparan sulfate regulates syndecan-1 function and cell behavior. J. Biol. Chem. 1994; 269: 13100–13106
   PubMed Web of Science ®Google Scholar
• Stanley M. J., Liebersbach B. F., Liu W., Anhalt D. J., Sanderson R. D. Heparan sulfate-mediated cell aggregation. Syndecans-1 and -4 mediate intercellular adhesion following their transfection into human B lymphoid cells. J. Biol. Chem. 1995; 270: 5077–5083
   PubMed Web of Science ®Google Scholar
• Liebersbach B. F., Sanderson R. D. Expression of syndecan-1 inhibits cell invasion into type I collagen. J. Biol. Chem. 1994; 269: 20013–20019
   PubMed Web of Science ®Google Scholar
• Mali M., Andtfolk H., Miettinen H. M., Jalkanen M. Suppression of tumor cell growth by syndecan- 1 ectodomain. J. Biol. Chem. 1994; 269: 27795–27798
   PubMed Web of Science ®Google Scholar
• Numa F., Hirabayashi K., Tsunaga N., Kato H., O'Rourke K., Shao H., Stechmann-Lebakken C., Varani J., Rapraeger A., Dixit V. M. Elevated levels of syndecan-1 expression confer potent serum-dependent growth in human 293t cells. Cancer Res. 1995; 55: 4676–4680
   PubMed Web of Science ®Google Scholar
• Santra M., Skorski T., Calabretta B., Lattime E. C., Iozzo R. V. De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells. Proc. Natl. Acad. Sci. USA 1995; 92: 7016–7020
   PubMed Web of Science ®Google Scholar
• Deluca A., Santra M., Baldi A., Giordano A., Iozzo R. V. Decorin induced growth suppression is associated with up-regulation of p21, an inhibitor of cyclin-dependent kinases. J. Biol. Chem. 1996; 271: 18961–18965
   PubMed Web of Science ®Google Scholar
• Mathiak M., Yenisey C., Grant D. S., Sharma B., Iozzo R. V. A role for perlecan in the suppression of growth and invasion in fibrosarcoma cells. Cancer Res. 1997; 57: 2130–2136
   PubMed Web of Science ®Google Scholar
• Smith K. G. C., Hewitson T. D., Nossal G. J. V., Tarlinton D. M. The phenotype and fate of the antibody-forming cells of the splenic foci. Eur. J. Immunol. 1996; 26: 444–448
   PubMed Web of Science ®Google Scholar
• Borset M., Lien E., Espevik T., Helseth E., Waage A., Sundan A. Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-met in human myeloma cell lines. J. Biol. Chem. 1996; 271: 24655–24661
   PubMed Web of Science ®Google Scholar
• Borset M., Hjorthhansen H., Seidel C., Sundan A., Waage A. Hepatocyte growth factor and its receptor c-met in multiple myeloma. Blood 1996; 88: 3998–4004
   PubMed Web of Science ®Google Scholar
• Seidel C., Borset M., Turesson I., Abildgaard N., Sundan A., Waage A. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood 1998; 91: 806–812
   PubMed Web of Science ®Google Scholar
• Kato M., Wang H., Kainulainen V., Fitzgerald M. L., Ledbetter S., Omitz D. M., Bernfield M. Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat. Med. 1998; 4: 691–697
   PubMed Web of Science ®Google Scholar
• Bataille R., Manolagas S. C., Berenson J. R. Pathogenesis and management of bone lesions in multiple myeloma. Hematol. Oncol. Clin. North Am. 1997; 11: 349–361
   PubMed Web of Science ®Google Scholar
• Bataille R., Chappard D., Marcelli C., Dessauw P., Baldet P., Sany J., Alexandre C. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J. Clin. Invest. 1991; 88: 62–66
   PubMed Web of Science ®Google Scholar
• Bataille R., Chappard D., Marcelli C., Dessauw P., Sany J., Baldet P., Alexandre C. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J. Clin. Oncol. 1989; 7: 1909–1914
   PubMed Web of Science ®Google Scholar
• Mundy G. R., Raisz L. G., Cooper R. A., Schechter G. P., Salmon S. E. Evidence for the secretion of an osteoclast stimulating factor in myeloma. N. Engl. J. Med. 1974; 291: 1041–1046
   PubMed Web of Science ®Google Scholar
• Kawano M., Yamamoto I., Iwato K., Tanaka H., Asaoku H., Tanabe O., Ishikawa H., Nobuyoshi M., Ohmoto Y., Hirai Y. Interleukin-1 beta rather than lymphotoxin as the major bone resorbing activity in human multiple myeloma. Blood 1989; 73: 1646–1649
   PubMed Web of Science ®Google Scholar
• Carter A., Merchav S., Silvian-Draxler I., Tatarsky I. The role of interleukin-1 and tumour necrosis factor-alpha in human multiple myeloma. Br. J. Haematol. 1990; 74: 424–431
   PubMed Web of Science ®Google Scholar
• Delaisse J. M., Eeckhout Y., Vaes G. Bone-resorbing agents affect the production and distribution of procollagenase as well as the activity of collagenase in bone tissue. Endocrinology 1988; 123: 264–276
   PubMed Web of Science ®Google Scholar
• Fuller K., Chambers T. J., Gallagher A. C. Heparin augments osteoclast resorption-stimulating activity in serum. J. Cell. Physiol. 1991; 147: 208–214
   PubMed Web of Science ®Google Scholar
• Chowdhury M. H., Hamada C., Dempster D. W. Effects of heparin on osteoclast activity. J. Bone Miner. Res. 1992; 7: 771–777
   PubMed Web of Science ®Google Scholar
• Shaughnessy S. G., Young E., Deschamps P., Hirsh J. The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood 1995; 86: 1368–1373
   PubMed Web of Science ®Google Scholar
• Chen Y., Bei M., Woo I., Satokata I., Maas R. Msxl controls inductive signaling in mammalian tooth morphogenesis. Development 1996; 122: 3035–3044
   PubMed Web of Science ®Google Scholar
• Gallo R., Kim C., Kokenyesi R., Adzick N. S., Bern-Field M. Syndecans- 1 and -4 are induced during wound repair of neonatal but not fetal skin. J. Invest. Dematol. 1996; 107: 676–683
   PubMed Web of Science ®Google Scholar
• Rettig M. B., Ma H. J., Vescio R. A., Pold M., Schiller G., Belson D., Savage A., Nishikubo C., Wu C., Fraser J., Said J. W., Berenson J. R. Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science 1997; 276: 1851–1854
   PubMed Web of Science ®Google Scholar
• Said J. W., Rettig M. R., Heppner K., Vescio R. A., Schiller G., Ma H. J., Belson D., Savage A., Shintaku I. P., Koeffler H. P., Asou H., Pinkus G., Pinkus J., Schrage M., Green E., Berenson J. R. Localization of Kaposi's sarcoma-associated herpesvirus in bone marrow biopsy samples from patients with multiple myeloma. Blood 1997; 90: 4278–4282
   PubMed Web of Science ®Google Scholar
• Shieh M. T., Spear P. G. Herpesvirus-induced cell fusion that is dependent on cell surface heparan sulfate or soluble heparin. J. Virol. 1994; 68: 1224–1228
   PubMed Web of Science ®Google Scholar
• Immergluck L. C., Domowicz M. S., Schwartz N. B., Herold B. C. Viral and cellular requirements for entry of herpes simplex virus type 1 into primary neuronal cells. J. Gen. Virol. 1998; 79: 549–559
   PubMed Web of Science ®Google Scholar
• Liu W. E.D., Litwack M. J., Stanley J. K., Langford Lander A. D., Sanderson R. D. Heparan sulfate proteoglycans as adhesive and anti-invasive molecules. Syndecans and glypicans have distinct functions. J. Biol. Chem. 1998; 273(22)825–22832
   Google Scholar